VIDA offers the VIDA Intelligence Portal, an AI-powered platform that supports clinical trial decentralization and improves site recruitment, onboarding, staff training, image data management and data quality. Five months after launching the Portal, demand expanded VIDA’s network to more than 1,000 sites and drove substantial increases in bookings and annual recurring revenue. The company also markets VIDA Insights, a complementary data-driven solution authorized for use in Japan in April 2022 to aid lung care teams at the point of care. VIDA is using product and commercial momentum to accelerate innovation and broader adoption in the biopharma market for clinical data intelligence. Leadership additions and planned strategic senior hires are intended to support rapid commercial growth and operational scale. The company is actively showcasing its solutions at industry conferences to drive awareness and adoption. Vida Diagnostics develops AI-powered CT imaging software and services to aid early detection, evaluation and treatment planning for patients with or at risk of respiratory and lung diseases. Led by CEO Susan A. Wood, Ph.D., the company targets conditions including emphysema, COPD, asthma, interstitial lung disease and lung cancer. Its software and services are FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, EEA, Canada and Australia. Vida plans to use the funds to accelerate development and commercialization of its solutions and to impact patient care for both traditional respiratory diseases and emergent COVID-19 conditions. The company received a $2M second close from OSF Ventures that augmented an $11M tranche announced the prior month, completing a $13M Series C funding round. Based in Coraville, Iowa, Vida is focusing on broader commercial adoption of its AI imaging solutions. Vida Diagnostics develops AI-powered CT imaging software and services to aid early detection, evaluation, and treatment planning for patients with or at risk of lung diseases. Its core product is the LungPrint® solution suite, which the company plans to commercialize more broadly and expand clinically. The company raised an $11M initial close of its Series C financing to accelerate commercialization and expand LungPrint’s clinical portfolio. Vida’s offerings are FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use. The technology targets conditions including emphysema, COPD, asthma, interstitial lung disease and lung cancer. The company is led by Susan A. Wood, Ph.D., CEO. Vida Diagnostics develops AI-powered lung analysis software called LungPrint, a fully automated analysis of inspiratory chest CT scans that flags lung density abnormalities indicative of emphysema or interstitial lung disease. The company positions its solution to improve patient outcomes, elevate quality of care, and lower overall health care costs by addressing the growing burden of pulmonary disease. Vida entered a strategic partnership with UnityPoint Health Ventures to develop and commercialize LungPrint and drive adoption across clinical settings. The partnership grants Vida access to UnityPoint Health’s multi-state network of hospitals and clinics and to clinical experts who will inform the company’s product roadmap and commercialization efforts. Vida also secured non-dilutive funding from the Iowa Economic Development Authority. The company is led by CEO Susan A. Wood, Ph.D., and is based in Coralville, Iowa. Vida Diagnostics offers a lung informatics solution that combines image analysis services (Precision Services) with software visualization and analytics (VIDA|vision). The product suite spans diagnostic and therapeutic planning applications for pulmonary disease management. VIDA|vision provides airway mapping software to guide bronchoscopic biopsy for suspected lung cancer and delivers advanced, clinically-validated measures to inform treatment selection for severe emphysema patients. The company serves clinicians treating lung cancer, COPD, and asthma. Vida intends to use the financing to hire additional personnel and enhance its clinical software and services. The company is led by President and CEO Susan A. Wood, Ph.D., and also maintains an office in Minneapolis, MN.

Total raised

$18M

Funding rounds

7

Latest round

Series C

Latest activity

Apr 2020